Clinical parameters and response
| Patient no. . | IT-rituximab dose, mg . | FcγRIIIA-158 . | Baseline serum rituximab concentration, ng/mL . | Decadron dose . | IOL status . | Brain status . | CSF status . | IOL response . | Brain response . | CSF response . | Overall response in brain and CSF . | Response duration . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10 | V/F | < 500 | 4 mg BID | − | + | + | NA | PD | CR | PD | NA |
| 2 | 10 | V/F | 1230 | None | − | − | + | NA | NA | CR | CR | 8 months |
| 3 | 10 | F/F | < 500 | None | − | − | + | NA | NA | SD | SD | NA |
| 4 | 25 | F/F | 1540 | None | − | + | − | NA | NA | NA | Extra-CNS PD | NA |
| 5 | 25 | V/V | 1740 | 6 mg TID | − | + | + | NA | PD | SD | PD | NA |
| 6 | 25 | V/F | 57 300 | 4 mg BID | − | + | + | NA | PD | CR | PD | NA |
| 7 | 25 | F/F | 19 800 | 2 mg BID | − | − | + | NA | CR | CR | CR | 0.5 month |
| 8 | 25 | V/F | < 500 | None | − | − | + | NA | NA | CR | CR | 1 month |
| 9 | 25 | V/F | 2510 | None | − | + | − | NA | CR | NA | CR | 3 months |
| 10 | 25 | V/V | 2100 | None | + | + | + | SD | PR | CR | PR | NA |
| 11 | 25 | V/F | < 500 | None | + | + | + | SD | CR | CR | CR | 1 month |
| 12 | 25 | F/F | 219 000 | None | − | − | + | NA | NA | CR | CR | > 5.5 months |
| 13 | 25 | V/F | 2600 | 2 mg BID | − | + | + | NA | PD | CR | PD | NA |
| 14 | 25 | F/F | 3990 | None | − | + | + | NA | PD | NA | PD | NA |
| Patient no. . | IT-rituximab dose, mg . | FcγRIIIA-158 . | Baseline serum rituximab concentration, ng/mL . | Decadron dose . | IOL status . | Brain status . | CSF status . | IOL response . | Brain response . | CSF response . | Overall response in brain and CSF . | Response duration . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10 | V/F | < 500 | 4 mg BID | − | + | + | NA | PD | CR | PD | NA |
| 2 | 10 | V/F | 1230 | None | − | − | + | NA | NA | CR | CR | 8 months |
| 3 | 10 | F/F | < 500 | None | − | − | + | NA | NA | SD | SD | NA |
| 4 | 25 | F/F | 1540 | None | − | + | − | NA | NA | NA | Extra-CNS PD | NA |
| 5 | 25 | V/V | 1740 | 6 mg TID | − | + | + | NA | PD | SD | PD | NA |
| 6 | 25 | V/F | 57 300 | 4 mg BID | − | + | + | NA | PD | CR | PD | NA |
| 7 | 25 | F/F | 19 800 | 2 mg BID | − | − | + | NA | CR | CR | CR | 0.5 month |
| 8 | 25 | V/F | < 500 | None | − | − | + | NA | NA | CR | CR | 1 month |
| 9 | 25 | V/F | 2510 | None | − | + | − | NA | CR | NA | CR | 3 months |
| 10 | 25 | V/V | 2100 | None | + | + | + | SD | PR | CR | PR | NA |
| 11 | 25 | V/F | < 500 | None | + | + | + | SD | CR | CR | CR | 1 month |
| 12 | 25 | F/F | 219 000 | None | − | − | + | NA | NA | CR | CR | > 5.5 months |
| 13 | 25 | V/F | 2600 | 2 mg BID | − | + | + | NA | PD | CR | PD | NA |
| 14 | 25 | F/F | 3990 | None | − | + | + | NA | PD | NA | PD | NA |
IOL indicates intraocular NHL; NA, not available; SD, stable disease; and PD, progressive disease.